DB
SYRS

Dmitry Balyasny’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Dmitry Balyasny’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,106
Closed -$124K – 3223
2024
Q1 		$124K Buy
+23,106
New +$160K ﹤0.01% 2480
2022
Q3 		– Sell
-1,483
Closed -$14K – 3337
2022
Q2 		$14K Buy
+1,483
New +$13.9K ﹤0.01% 2533
2018
Q2 		– Sell
-1,030
Closed -$134K – 2215
2018
Q1 		$134K Sell
1,030
-1,900
-65% -$208K ﹤0.01% 1806
2017
Q4 		$285K Buy
+2,930
New +$394K ﹤0.01% 1767

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Dmitry Balyasny's SYRS Position: Q2 2024 in Review

Dmitry Balyasny sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 23,106 shares — an estimated $124K sold.

Dmitry Balyasny first reported a position in SYRS in Q4 2017 and held it in 4 quarters. The position peaked at $285K in Q4 2017. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

  • Dmitry Balyasny reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 23,106 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $124K.
  • Dmitry Balyasny first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Dmitry Balyasny's Syros Pharmaceuticals, Inc. Common Stock position peaked at $285K in Q4 2017.
  • 70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.